1:30Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company’s strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex’s product pipeline is focused on viral diseases, inflammation, autoimmune diseases, cancer, pain and cystic fibrosis. Vertex co-discovered the HIV protease inhibitor, Lexiva, with GlaxoSmithKline. Lexiva is a registered trademark of the GlaxoSmithKline group of companies

1:30 MannKind Corporation (Nasdaq: MNKD - News) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its pipeline includes AFRESA, which has completed Phase 3 clinical trials, and MKC253, which is currently in phase 1 clinical trials. Both of these investigational products are being evaluated for their safety and efficacy in the treatment of diabetes.

1:30 Molina Healthcare, Inc. is a multi-state managed care organization that arranges for the delivery of health care services to persons eligible for Medicaid, Medicare, and other government-sponsored programs for low-income families and individuals. Molina Healthcare’s ten licensed health plan subsidiaries in California, Florida, Michigan, Missouri, Nevada, New Mexico, Ohio, Texas, Utah, and Washington currently serve approximately 1.2 million members

2...Kass shorts this..NEW YORK (AP) -- Shares of dental-products provider Henry Schein Inc. fell Wednesday after the company warned that a weaker sales market will hurt revenue in the fourth quarter, prompting it to cut jobs. Related Quotes Symbol Price Change HSIC 36.75 -0.21 {"s" : "hsic","k" : "c10,l10,p20,t10","o" : "","j" : ""} Its shares fell $4.62, or 10 percent, to close at $41.63. The Melville, N.Y., company, which distributes a range of dental products from X-ray equipment to surgical tools, plans to cut 300 jobs, or 2.5 percent of its work force, in anticipation of a weak market. It employs more than 12,000 people and has operations or affiliates in 20 countries. Henry Schein cut 2008 profit guidance to between $2.94 and $2.96 per share, down from prior guidance of $2.93 to $3 per share. Analysts polled by Thomson Reuters expect profit of $2.97. It also set 2009 guidance of $3.27 to $3.36 per share, below Wall Street forecasts for $3.39 per share. The cut guidance followed a positive third-quarter financial report, where profit and revenue met forecasts. Robert W. Baird analyst Jeff D. Johnson, brushed off the guidance, reaffirming a "Outperform" rating and a $62 price target. "We worry some investors may be disappointed with third-quarter dental-equipment organic growth and 2009 guidance, but both met our expectations and, in our opinion, reflect Henry Schein's ongoing ability to deliver healthy growth despite the challenging environment." The company continues to gain ground in its core North American dental business, he added, through a combination of improved operating performance and exclusive distribution agreements. Goldman Sachs analyst Randall Stanicky reaffirmed a "Neutral" rating, saying the company's initial 2009 outlook reflects a tough environment.

2 Located in the Nashville, Tennessee suburb of Franklin, Community Health Systems, Inc. is the largest publicly-traded hospital company in the United States and a leading operator of general acute care hospitals in non-urban and mid-size markets throughout the country. Through its subsidiaries, the Company currently owns, leases or operates 118 hospitals in 29 states with over 17,500 licensed beds. Its hospitals offer a broad range of inpatient and surgical services, outpatient treatment and skilled nursing care. In addition, through its QHR subsidiary, the Company provides management and consulting services to over 160 independent non-affiliated general acute care hospitals located throughout the United States

2 Here are my notes on this from JPMorgan Conf..hmsy Unemployment Play...This is a company that focus on Payment errors in Medicaid by finding people who have OTHER insurance and Medicad paid first. How do they tap this...New Products, get more medicaid lives, new contracts....Enrollment is growing in Medicaid....few of the contracts HMO's...8% grow in Medicaid and they should benefit..they also do data mining for errors, fraud and abuse, Every year they sell new products to the States, VA, etc...with rising unemployment more people into medicaid program, so this company ACTUALLY BENEFITS from high unemployment numbers..lol...With State deficits there will be a strong focus for the States to look for pennies...therefore HMSY makes sense. Electronic medical Records will actually help them cuz they can cut margins...Obama Plans could bring more people into Medicaid or Govt Medical Plans....The states can't really cut Medicaid cuz of the 50% Govt Matching program and a lot of lobbiest that would stop the cuts, also anyone can go to the emerg room....so HMSY makes sense for the States to get in hopes of getting some money from insurance. Obama...requires all children to have coverage, requires employers to over insurance. This Company is over 20 years old and have over 120 contracts and a decade data base that no one else has so they can match it fast and cheap...no competitior can even compete cuz they own this party..small room...3/4 full....guidance...press release today upped guidance...need to get a copy of that. .old notes..the nation's leader in coordination of benefits and program integrity services for government healthcare programs. The company's clients include health and human services programs in more than 40 states, 80 Medicaid managed care plans, the Centers for Medicare and Medicaid Services (CMS), and Veterans Administration facilities. HMS helps ensure that healthcare claims are paid correctly and by the responsible party. As a result of the company's services, government healthcare programs recover over $1 billion annually, and avoid billions of dollars more in erroneous payments.

2:30 From Barrons..this is what they will be looking for..DEAL MAY NEED UP TO $35 BILL IN FINANCING The next big test for just how accommodating the corporate borrowing market may be in 2009 - meaning, has it improved at all? - could come courtesy of an anticipated bid by Roche for the balance of Genentech (DNA). The Swiss drug maker has exprssed further interest in rolling up the 44% of the U.S. biotech that it doesn’t currently hold, according to the FT.com website. Such a deal could cost Roche as much as $44 billion - perhaps even $50 billion if Genentech resisted the overtures - of which as much as $35 billion might have to come from debt financing, depending on other initiatives Roche might take. The company could scrap its dividend and use the capital to help finance a takeover. The corporate financing market ground to a half in the second half of last year, one of the factors that contributed to the dwindling M&A market as the year wore on. (The fact that few prospective buyers wanted to commit capital to something as risky as an acquisition certainly played a role in the demise of M&A.) Presuming the FT account is borne out, and Roche proceeded with a bid for DNA, it could prove a critical litmus test for the corporate borrowing market

2:30...ok ok this stock is up 25% in AH the day before it is going to present...no news that I can see...either someone knows something or really playing around a lot..Life Technologies Corporation operates as a global biotechnology tools company focused on improving the human condition. Its systems, consumables, and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies� customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. The company has a presence in approximately 100 countries, and possesses a growing intellectual property estate of approximately 3,600 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems, Inc. The company is based in Carlsbad, California